Navigation Links
Antisense therapeutics scientist out to pull more big deals
Date:3/27/2008

Aiming for more major licensing deals like the one his company recently secured with top 20 global pharmaceutical company, Teva, is front of mind for rising Australian biotechnology star, Antisense Therapeutics Ltd (ASX code: ANP)Research Director Dr Christopher Wraight when he meets with leading industry figures in the US in May.

One of two Australian life scientists chosen from a highly competitive field of candidates for the prestigious 2008 Advancing BioBusiness Award, Dr Wraight will attend the worlds largest biotechnology meeting, the Biotechnology Industry Organisation (BIO) convention, which attracts over 22,000 delegates from around the globe.

A tailored program of meetings will also be scheduled for him with leading American players including venture capital firms, research institutes, biotechnology entrepreneurs and biopharmaceutical companies, to help build valuable international networks, knowledge and collaborations.

The Advancing BioBusiness Award is an innovative scheme by Merck Sharp & Dohme and Advance, a dynamic, diverse global community of Australian professionals overseas committed to advancing Australia and Australians.

Through the Advancing BioBusiness Award, Dr Wraight said he wants to expand important global connections for Australian science and help facilitate more international business by better understanding what US pharmaceutical companies are looking for in new drug therapies at each stage of what is typically a 10-15 year development process.

Our ultimate customer is the patient. For most Australian pharmaceutical biotechs, however, big pharmaceutical companies are the first customers we need to think about. To provide better drugs for patients we first need to build better research and development programs to attract the best commercialisation partners, Dr Wraight said.

Before they license drugs from biotechs, pharmaceutical companies scrutinise our drug R&D programs with very demanding and sophisticated due diligence processes around very long-term planning horizons. Biotechs sometimes fall at the last hurdle, failing to execute a deal because decisions taken early in their drug development program did not anticipate the future needs of their prospective partner, he said.

Dr Wraight said that establishing relationships with a range of key US decision-makers will facilitate soundconsultation throughout each stage of development to optimise eventual success at the negotiating table.

Senator Kim Carr, Minister for Innovation, Industry, Science and Research, said:

"The Advancing BioBusiness Award complements the Rudd Government's policy of promoting innovation and commercialisation in the biotechnology and pharmaceutical sector, encouraging closer links between Australian biotech and global pharmaceutical companies, and helping Australian biotechs access global supply chains."

Dr Phil Kearney, Merck Sharp & Dohmes manager for external scientific affairs, said Australia is recognised for its excellence in medical research and its vigorous and creative biopharmaceutical industry. However the number of drug development projects which reach advanced clinical development is only a quarter of what would be predicted on the basis of our output in scientific literature.

By immersing two of our top biotechnology people in successful commercial research centres in the United States, and providing them with opportunities to share their learning back at home, we aim to build a stronger Australiancapability to win in this highly competitive global knowledge market, he said.

The other recipient of the 2008 Advancing BioBusiness Award is Dr Raisa Monteiro, Research Director of DendriMed.


'/>"/>

Contact: Jackie Crossman
jackie@crossmancommunications.com.au
61-293-610-519
Research Australia
Source:Eurekalert

Related medicine news :

1. Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
2. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
3. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
4. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
5. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
7. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
8. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
9. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
10. Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Childrens Hospital at Stanford
11. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: